Skip to content

Optimising Renal Tumour Management Through Artificial Intelligence Modules

Mutimodal Artificial Intelligence for Optimising Renal Tumour Management: Diagnosis, Surgery and Prognosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06714916
Enrollment
2100
Registered
2024-12-04
Start date
2025-01-01
Completion date
2033-12-31
Last updated
2025-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pathology, Renal Cell Cancer, Renal Neoplasms

Keywords

Articicial Intelligence, Renal tumors, Prediction Model, Surgery, Radiomics, Pathomics

Brief summary

The goal of this observational study is to improve the management of people with renal tumour by multimodal artificial intelligence(AI). It will also measure the accuracy of the predictions from AI models. The main questions it aims to answer are: 1. whether the AI module can accurately provide tumor-related information such as Benign or malignant, subtypes, grading, stage, etc. by learning from preoperative CT images. 2. whether the AI module can help clinicians find out the most suitable surgical programme for people with renal tumor. 3. whether the AI module can integrate CT images and pathology slides, offering supplementary prognostic information to improve postoperative survival. Participants who complete a CT(usually Contrast-enhanced CT, CECT) examination and undergo radical or partial nephrectomy will carry out active surveillance and record postoperative survival data for 5 years.

Detailed description

In this study, AI model will explore and clarify features in renal tumor CT images and pathological images that are difficult to detect manually, and then correlate them with clinical outcomes, thereby improving the diagnosis and treatment process for renal tumors. Firstly, the model can accurately distinguish renal tumor subtypes and predict stage, grade, and complexity so as to svoid misdiagnosis and assist clinicians in formulating treatment plans. Secondly, by learning from surgical videos, the model can provide additional information during surgerys, such as important anatomical landmarks, location of tumors. Finally, combining radiomics and pathomics, the model can differentiate between high-risk and low-risk patients after surgery, thus providing personalized prognostic guidance.

Interventions

None listed

Sponsors

Shao Pengfei
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with renal tumor which can be treated by surgery; * Complete CECT within 30 days before surgery; * Patients who fully understand this study and sign the informed consent;

Exclusion criteria

* Patients with any item missing from the baseline clinical and pathological information; * Patients who has already metastasized by the time the tumor is discovered; * Previous treatment in any form, including surgery, targeted therapy and immunotherapy;

Design outcomes

Primary

MeasureTime frameDescription
Assessing the performance of AI models by the AUC comprehensive assessment modelFrom enrollment to the end of 5-years' follow upAUC refers to the area under the ROC (Receiver Operating Characteristic) curve, which indicates the performance of the model in predicting immunohistochemistry-related pathological information of prostate cancer after surgery, and the AUC ranges from 0-1, with the larger value indicating the better prediction effect.

Secondary

MeasureTime frameDescription
Assessing the model's performance to predict participants' prognosis post-surgery by Kaplan-Meier Survival AnalysisFrom enrollment to the end of 5-years' follow upKaplan-Meier Survival Analysis s a non-parametric statistic mainly used to figure out factors which indicate survival.

Countries

China

Contacts

Primary ContactShao Pengfei, Professor
spf032@hotmail.com+8613851925825
Backup ContactMiao Haoqi, Postgraduate
mhq@stu.njmu.edu.cn+8613276636957

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026